Bedossa Pierre, Moucari Rami, Chelbi Emna, Asselah Tarik, Paradis Valerie, Vidaud Michel, Cazals-Hatem Dominique, Boyer Nathalie, Valla Dominique, Marcellin Patrick
Service d'Anatomie Pathologique, CNRS UMR 8149, Clichy, France.
Hepatology. 2007 Aug;46(2):380-7. doi: 10.1002/hep.21711.
Although steatosis is a common histological feature in chronic hepatitis C (CHC), nonalcoholic steatohepatitis (NASH) has not yet been clearly characterized in this context. The aim of this prospective study was to investigate the characteristics of patients with NASH and CHC. Biopsies were categorized as CHC alone (178 patients [57%]), CHC+steatosis (94 patients [34%]), or CHC+NASH (24 patients [9%]). Patients with CHC+NASH had significantly higher AST and triglyceride levels and lower high-density lipoprotein (HDL) cholesterol or total cholesterol than patients with CHC+steatosis. They also showed more steatosis and higher METAVIR fibrosis stage than patients with CHC+steatosis. Genotype 3 was more frequent in patients with CHC+NASH than in patients with CHC+steatosis or CHC alone. Patients with genotype 3 and CHC+NASH were similar to those with CHC+steatosis or with CHC alone according to triglyceride or the homeostasis model for assessment of insulin resistance (HOMA-IR), whereas in patients with genotype 1, HOMA-IR and triglyceride increased progressively from CHC alone to CHC+steatosis to CHC+NASH. In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor.
Patients with CHC+NASH differ significantly from those with CHC+steatosis and CHC alone in terms of biological and metabolic parameters and more advanced histopathological lesions. NASH is more common in genotype 3 and is not associated with metabolic dysfunctions in this subgroup, suggesting that NASH may complicate steatosis in CHC irrespective of etiology of steatosis.
虽然脂肪变性是慢性丙型肝炎(CHC)常见的组织学特征,但在此背景下非酒精性脂肪性肝炎(NASH)尚未得到明确界定。这项前瞻性研究的目的是调查NASH和CHC患者的特征。活检标本分为单纯CHC(178例患者[57%])、CHC+脂肪变性(94例患者[34%])或CHC+NASH(24例患者[9%])。与CHC+脂肪变性患者相比,CHC+NASH患者的谷草转氨酶(AST)和甘油三酯水平显著更高,高密度脂蛋白(HDL)胆固醇或总胆固醇更低。他们还比CHC+脂肪变性患者表现出更多的脂肪变性和更高的METAVIR纤维化分期。CHC+NASH患者中基因型3比CHC+脂肪变性患者或单纯CHC患者更常见。根据甘油三酯或胰岛素抵抗评估的稳态模型(HOMA-IR),基因型3和CHC+NASH患者与CHC+脂肪变性患者或单纯CHC患者相似,而在基因型1患者中,HOMA-IR和甘油三酯从单纯CHC到CHC+脂肪变性再到CHC+NASH逐渐升高。多变量分析中,甘油三酯和HDL胆固醇是基因型1患者NASH的预测指标,而在基因型3患者中,AST是唯一的预测指标。
CHC+NASH患者在生物学和代谢参数以及更严重的组织病理学病变方面与CHC+脂肪变性患者和单纯CHC患者有显著差异。NASH在基因型3中更常见,且在该亚组中与代谢功能障碍无关,这表明无论脂肪变性的病因如何,NASH可能使CHC中的脂肪变性复杂化。